Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

[1]  Afsaneh Barzi,et al.  Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. , 2019, The Lancet. Oncology.

[2]  Robin L. Jones,et al.  Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). , 2019, Journal of Clinical Oncology.

[3]  M. Heinrich,et al.  Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry , 2019, Clinical Sarcoma Research.

[4]  M. Heinrich,et al.  Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry , 2019, Clinical Sarcoma Research.

[5]  W. Tap,et al.  VOYAGER: an open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  W. Tap,et al.  VOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Benjamin,et al.  Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients , 2017, Scientific Reports.

[8]  I. Judson,et al.  UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST) , 2017, Clinical Sarcoma Research.

[9]  J. Blay,et al.  Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet. Oncology.

[10]  J. Blay,et al.  Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. , 2016, The Lancet. Oncology.

[11]  S. Krishnamoorthy,et al.  Management of regorafenib-related toxicities: a review , 2015, Therapeutic advances in gastroenterology.

[12]  A. Maguire,et al.  Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model , 2014, BMC Cancer.

[13]  E. Tetzlaff,et al.  Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor , 2013, Journal of the advanced practitioner in oncology.

[14]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[15]  P Reichardt,et al.  Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Qian Wang,et al.  Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[18]  Martin Büchert,et al.  A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[19]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[20]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[21]  F. Duffaud.  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Owzar,et al.  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .

[23]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[25]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[26]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[27]  G. Demetri,et al.  Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.

[28]  E. van den Berg,et al.  Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[30]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..